Drugs currently in Phase II clinical trials for cocaine addiction

Expert Opinion on Investigational Drugs

Volumn 23, Issue 8, 2014, Pages 1105-1122

  Kim, Jee Hyun ^a,b   Lawrence, Andrew J ^b  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Addiction; Clinical trials; Cocaine; Drug pipelines; Therapeutics

Indexed keywords

AMPHETAMINE; ARIPIPRAZOLE; BACLOFEN; BUSPIRONE; CANDESARTAN; CARVEDILOL; DOXAZOSIN; DRUGS USED IN THE TREATMENT OF ADDICTION; KETAMINE; LEVODOPA; LIDOCAINE; LISDEXAMFETAMINE; MIFEPRISTONE; MODAFINIL; NEPICASTAT; ONDANSETRON; PROPRANOLOL; PSILOCYBINE; ROPINIROLE; TOPIRAMATE; VARENICLINE; AMPHETAMINE DERIVATIVE; FRUCTOSE;

COCAINE DEPENDENCE; DOPAMINERGIC ACTIVITY; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DEPENDENCE TREATMENT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG SOLUBILITY; HUMAN; NEUROCHEMISTRY; PHASE 2 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SMOKING; SUBSTITUTION THERAPY; SUSTAINED RELEASE FORMULATION; SYSTEMIC CIRCULATION; WITHDRAWAL SYNDROME; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN; COCAINE-RELATED DISORDERS; DRUG DESIGN; DRUG EFFECTS; PATHOLOGY; PATHOPHYSIOLOGY;

AMPHETAMINES; ANIMALS; BRAIN; CLINICAL TRIALS, PHASE II AS TOPIC; COCAINE-RELATED DISORDERS; DRUG DESIGN; FRUCTOSE; HUMANS; QUALITY OF LIFE;

EID: 84904316822     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.915312     Document Type: Review

References (179)

1. Kalivas PW, Volkow ND. The neural basis of addiction: A pathology of motivation and choice. Am J Psychiatry 2005;162: 1403-13
2. Pouletty P. Drug addictions: Towards socially accepted and medically treatable diseases. Nat Rev Drug Discov 2002;1: 731-6
3. United Nations Office of Drugs and Crime. World Drug Report 2012;134: 260-77
4. Degenhardt L, Bucello C, Calabria B, et al. What data are available on the extent of illicit drug use and dependence globally? Results of four systematic reviews. Drug Alcohol Depend 2011;117: 85-101
5. Ross J. Illicit drug use in Australia: Epidemiology, use patterns and associated harm. 2nd edition. National Drug and Alcohol Research Centre; Barton: 2007
6. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Treatment Episode Data Set (TEDS) 1998-2008. 2010;1-123
7. McLellan AT, Lewis DC, O'Brien CP, Kleber HD. Drug dependence, a chronic medical illness: Implications for treatment, insurance, and outcomes evaluation. JAMA 2000;284: 1689-95
8. Available from: Http: //clinicaltrials.gov/
9. Haile CN, Mahoney JJ III, Newton TF, De La Garza R. Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: Focus on dopamine, norepinephrine and glutamate. Pharmacol Ther 2012;134: 260-77
10. Levey AI, Hersch SM, Rye DB, et al. Localization of D1 and D2 dopamine receptors in brain with subtype-specific antibodies. Proc Natl Acad Sci USA 1993;90: 8861-5
11. Eagle DM, Wong JCK, Allan ME, et al. Contrasting roles for dopamine D1 and D2 receptor subtypes in the dorsomedial striatum but not the nucleus accumbens core during behavioral inhibition in the stop-signal task in rats. J Neurosci 2011;31: 7349-56
12. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 1988;85: 5274-8
13. Goldstein RZ, Volkow ND. Drug addiction and its underlying neurobiological basis: Neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry 2002;159: 1642-52
14. Kalivas PW, Volkow N, Seamans J. Unmanageable motivation in addiction: A pathology in prefrontal-Accumbens glutamate transmission. Neuron 2005;45: 647-50
15. Volkow ND, Fowler JS, Wolf AP, et al. Effects of chronic cocaine abuse on postsynaptic dopamine receptors. Am J Psychiatry 1990;147: 719-24
16. Volkow ND, Fowler JS, Wang G-J, et al. Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. Synapse 1993;14: 169-77
17. Volkow ND, Wang GJ, Fowler JS, et al. Decreased striatal dopaminergic responsiveness in detoxified cocainedependent subjects. Nature 1997;386: 830-3
18. Martinez D, Broft A, Foltin RW, et al. Cocaine dependence and D2 receptor availability in the functional subdivisions of the striatum: Relationship with cocaine-seeking behavior. Neuropsychopharmacology 2004;29: 1190-202
19. Martinez D, Slifstein M, Narendran R, et al. Dopamine D1 receptors in cocaine dependence measured with PET and the choice to self-Administer cocaine. Neuropsychopharmacology 2009;34: 1774-82
20. Meador-Woodruff JH, Little KY, Damask SP, et al. Effects of cocaine on dopamine receptor gene expression: A study in the postmortem human brain. Biol Psychiatry 1993;34: 348-55
21. Malison RT, Best SE, Van Dyck CH, et al. Elevated striatal dopamine transporters during acute cocaine abstinence as measured by [123I]-CIT SPECT. Am J Psychiatry 1998;155: 832-4
22. Crits-Christoph P, Newberg A, Wintering N, et al. Dopamine transporter levels in cocaine dependent subjects. Drug Alcohol Depend 2008;98: 70-6
23. Wang G-J, Volkow ND, Fowler JS, et al. Cocaine abusers do not show loss of dopamine transporters with age. Life Sci 1997;61: 1059-65
24. Narendran R, Lopresti BJ, Martinez D, et al. In vivo evidence for low striatal vesicular monoamine transporter 2 (VMAT2) availability in cocaine abusers. Am J Psychiatry 2012;169: 55-63
25. Little KY, Krolewski DM, Zhang L, Cassin BJ. Loss of striatal vesicular monoamine transporter protein (VMAT2) in human cocaine users. Am J Psychiatry 2003;160: 47-55
26. Wilson JM, Shannak K, Kish SJ, et al. Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users. Ann Neurol 1996;40: 428-39
27. Kish SJ, Robitaille Y, El-Awar M, et al. Striatal monoamine neurotransmitters and metabolites in dominantly inherited olivopontocerebellar atrophy. Neurology 1992;42: 1573
28. Teneud LM, Baptista T, Murzi E, et al. Systemic and local cocaine increase extracellular serotonin in the nucleus accumbens. Pharmacol Biochem Behav 1996;53: 747-52
29. Jacobsen LK, Staley JK, Malison RT, et al. Elevated central serotonin transporter binding availability in acutely abstinent cocaine-dependent patients. Am J Psychiatry 2000;157: 1134-40
30. Little KY, Patel UN, Clark TB, Butts JD. Alteration of brain dopamine and serotonin levels in cocaine users: A preliminary report. Am J Psychiatry 1996;153: 1216-18
31. Matuskey D, Bhagwagar Z, Planeta B, et al. Reductions in brain 5-HT1B receptor availability in primarily cocainedependent humans. Biol Psychiatry 2014; In press
32. Ke Y, Streeter CC, Nassar LE, et al. Frontal lobe GABA levels in cocaine dependence: A two-dimensional, Jresolved magnetic resonance spectroscopy study. Psychiatry Res Neuroimaging 2004;130: 283-93
33. Kalivas PW, Volkow ND. New medications for drug addiction hiding inglutamatergic neuroplasticity. Mol Psychiatry 2011;16: 974-86
34. Bliss TV, Collingridge GL. A synaptic model of memory: Long-Term potentiation in the hippocampus. Nature 1993;361: 31-9
35. Royer S, Pare D. Conservation of total synaptic weight through balanced synaptic depression and potentiation. Nature 2003;422: 518-22
36. Stuber GD, Hnasko TS, Britt JP, et al. Dopaminergic terminals in the nucleus accumbens but not the dorsal striatum corelease glutamate. J Neurosci 2010;30: 8229-33
37. Yang S, Salmeron BJ, Ross TJ, et al. Lower glutamate levels in rostral anterior cingulate of chronic cocaine users-A 1H-MRS study using TE-Averaged PRESS at 3 T with an optimized quantification strategy. Psychiatry Res Neuroimaging 2009;174: 171-6
38. Li S-J, Wang Y, Pankiewicz J, Stein EA. Neurochemical adaptation to cocaine abuse: Reduction of N-Acetyl aspartate in thalamus of human cocaine abusers. Biol Psychiatry 1999;45: 1481-7
39. Hetherington HP, Pan JW, Telang F, et al. Reduced brain GABA levels in cocaine abusers. Proc Intern Soc Magn Reson Med 2000;523
40. Kreek MJ, Bart G, Lilly C, et al. Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacol Rev 2005;57: 1-26
41. Jay TM. Dopamine: A potential substrate for synaptic plasticity and memory mechanisms. Prog Neurobiol 2003;69: 375-90
42. Zolkowska D, Jain R, Rothman RB, et al. Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil. J Pharmacol Exp Ther 2009;329: 738-46
43. Murillo-Rodrìguez E, Haro R, Palomero-Rivero M, et al. Modafinil enhances extracellular levels of dopamine in the nucleus accumbens and increases wakefulness in rats. Behav Brain Res 2007;176: 353-7
44. Madras BK, Xie Z, Lin Z, et al. Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J Pharmacol Exp Ther 2006;319: 561-9
45. Dopheide MM, Morgan RE, Rodvelt KR, et al. Modafinil evokes striatal [3H]dopamine release and alters the subjective properties of stimulants. Eur J Pharmacol 2007;568: 112-23
46. Minzenberg MJ, Carter CS. Modafinil: A review of neurochemical actions and effects on cognition. Neuropsychopharmacology 2007;33: 1477-502
47. Korotkova TM, Klyuch BP, Ponomarenko AA, et al. Modafinil inhibits rat midbrain dopaminergic neurons through D2-like receptors. Neuropharmacology 2007;52: 626-33
48. Nelson AB, Hang GB, Grueter BA, et al. A comparison of striatal-dependent behaviors in wild-Type and hemizygous Drd1a and Drd2 BAC transgenic mice. J Neurosci 2012;32: 9119-23
49. Ball KT, Combs TA, Beyer DN. Opposing roles for dopamine D1-And D2-like receptors in discrete cue-induced reinstatement of food seeking. Behav Brain Res 2011;222: 390-3
50. Ferraro L, Fuxe K, Tanganelli S, et al. Amplification of cortical serotonin release: A further neurochemical action of the vigilance-promoting drug modafinil. Neuropharmacology 2000;39: 1974-83
51. Ferraro L, Antonelli T, Tanganelli S, et al. The vigilance promoting drug modafinil increases extracellular glutamate levels in the medial preoptic area and the posterior hypothalamus of the conscious rat: Prevention by local GABAA receptor blockade. Neuropsychopharmacology 1999;20: 346-56
52. Wong YN, King SP, Simcoe D, et al. Open-label, single-dose Pharmacokinetic study of modafinil tablets: Influence of age and gender in normal subjects. J Clin Pharmacol 1999;39: 281-8
53. Jasinski DR. An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J Psychopharmacol 2000;14: 53-60
54. Donovan JL, DeVane CL, Malcolm RJ, et al. Modafinil influences the pharmacokinetics of intravenous cocaine in healthy cocaine-dependent volunteers. Clin Pharmacokinet 2005;44: 753-65
55. Dackis CA, Lynch KG, Yu E, et al. Modafinil and cocaine: A double-blind, placebo-controlled drug interaction study. Drug Alcohol Depend 2003;70: 29-37
56. Malcolm R, Swayngim K, Donovan JL, et al. Modafinil and cocaine interactions. Am J Drug Alcohol Abuse 2006;32: 577-87
57. Hart CL, Haney M, Vosburg SK, et al. Smoked cocaine self-Administration is decreased by modafinil. Neuropsychopharmacology 2008;33: 761-8
58. Dackis CA, Kampman KM, Lynch KG, et al. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 2005;30: 205-11
59. Anderson AL, Reid MS, Li S-H, et al. Modafinil for the treatment of cocaine dependence. Drug Alcohol Depend 2009;104: 133-9
60. Schmitz JM, Green CE, Stotts AL, et al. A two-phased screening paradigm for evaluating candidate medications for cocaine cessation or relapse prevention: Modafinil, levodopa-carbidopa, naltrexone. Drug Alcohol Depend 2014;136: 100-7
61. Baranski JV, Pigeau R, Dinich P, Jacobs I. Effects of modafinil on cognitive and meta-cognitive performance. Hum Psychopharmacol Clin Exp 2004;19: 323-32
62. Turner DC, Robbins TW, Clark L, et al. Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology (Berl) 2003;165: 260-9
63. Kalechstein AD, Mahoney JJ III, Yoon JH, et al. Modafinil, but not escitalopram, improves working memory and sustained attention in long-Term, high-dose cocaine users. Neuropharmacology 2013;64: 472-8
64. Moeller FG, Steinberg JL, Schmitz JM, et al. Working memory fMRI activation in cocaine-dependent subjects: Association with treatment response. Psychiatry Res Neuroimaging 2010;181: 174-82
65. Ma L, Steinberg JL, Hasan KM, et al. Stochastic dynamic causal modeling of working memory connections in cocaine dependence. Hum Brain Mapp 2012;35: 760-78
66. Winhusen TM, Somoza EC, Lewis DF, et al. Frontal systems deficits in stimulant-dependent patients: Evidence of pre-illness dysfunction and relationship to treatment response. Drug Alcohol Depend 2013;127: 94-100
67. Miller GM. The emerging role of trace amine-Associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity. J Neurochem 2010;116: 164-76
68. Fleckenstein AE, Volz TJ, Riddle EL, et al. New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol 2007;47: 681-98
69. Stoops WW, Glaser PE, Fillmore MT, Rush CR. Reinforcing, subject-rated, performance and physiological effects of methylphenidate and d-Amphetamine in stimulant abusing humans. J Psychopharmacol 2004;18: 534-43
70. Rush CR, Stoops WW, Hays LR. Cocaine effects during d-Amphetamine maintenance: A human laboratory analysis of safety, tolerability and efficacy. Drug Alcohol Depend 2009;99: 261-71
71. Wilens TE, Adler LA, Adams J, et al. Misuse and diversion of stimulants prescribed for ADHD: A systematic review of the literature. J Am Acad Child Adolesc Psychiatry 2008;47: 21-31
72. Rush CR, Stoops WW, Sevak RJ, Hays LR. Cocaine choice in humans during D-Amphetamine maintenance. J Clin Pharmacol 2010;30: 152-9
73. Grabowski J, Rhoades H, Stotts A, et al. Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: Two double-blind randomized clinical trials. Neuropsychopharmacology 2004;29: 969-81
74. Grabowski J, Rhoades H, Schmitz J, et al. Dextroamphetamine for cocainedependence treatment: A double-blind randomized clinical trial. J Clin Pharmacol 2001;21: 522-6
75. Shearer J, Wodak A, van Beek I, et al. Pilot randomized double blind placebocontrolled study of dexamphetamine for cocaine dependence. Addiction 2003;98: 1137-41
76. Castells X, Casas M, Vidal X, et al. Efficacy of central nervous system stimulant treatment for cocaine dependence: A systematic review and meta-Analysis of randomized controlled clinical trials. Addiction 2007;102: 1871-87
77. Pèrez-Mañà C, Castells X, Vidal X, et al. Efficacy of indirect dopamine agonists for psychostimulant dependence: A systematic review and meta-Analysis of randomized controlled trials. J Subst Abuse Treat 2011;40: 109-22
78. Rosen H, Flemenbaum A, Slater VL. Clinical trial of carbidopa-{l}-dopa combination for cocaine abuse. Am J Psychiatry 1986;143: 1493
79. Wolfsohn R, Angrist B. A pilot trial of levodopa/carbidopa in early cocaine abstinence. J Clin Pharmacol 1990;10: 440-2
80. Wolfsohn R, Sanfilipo M, Augrist B. A placebo-controlled trial of L-dopa/ carbidopa in early cocaine abstinence. Neuropsychopharmacology 1993;9: 49-53
81. Shoptaw S, Watson DW, Reiber C, et al. Randomized controlled pilot trial of cabergoline, hydergine and levodopa/ carbidopa: Los Angeles Cocaine Rapid Efficacy Screening Trial (CREST). Addiction 2005;100: 78-90
82. Mooney ME, Schmitz JM, Moeller FG, Grabowski J. Safety, tolerability and efficacy of levodopa-carbidopa treatment for cocaine dependence: Two doubleblind, randomized, clinical trials. Drug Alcohol Depend 2007;88: 214-23
83. Meini M, Capovani B, Sbrana A, et al. A pilot open-label trial of ropinirole for cocaine dependence. Am J Addict 2008;17: 165-6
84. Meini M, Moncini M, Cecconi D, et al. Aripiprazole and ropinirole treatment for cocaine dependence: Evidence from a pilot study. Curr Pharm Des 2011;17: 1376-83
85. Schmitz JM, Mooney ME, Moeller FG, et al. Levodopa pharmacotherapy for cocaine dependence: Choosing the optimal behavioral therapy platform. Drug Alcohol Depend 2008;94: 142-50
86. Schmitz JM, Lindsay JA, Stotts AL, et al. Contingency management and levodopacarbidopa for cocaine treatment: A comparison of three behavioral targets. Exp Clin Psychopharmacol 2010;18: 238-44
87. Stanley WC, Li B, Bonhaus DW, et al. Catecholamine modulatory effects of nepicastat (RS-25560-197), a novel, potent and selective inhibitor of dopamine-beta-hydroxylase. Br J Pharmacol 1997;121: 1803-9
88. Devoto P, Flore G, Saba P, et al. The dopamine beta-hydroxylase inhibitor nepicastat increases dopamine release and potentiates psychostimulant-induced dopamine release in the prefrontal cortex. Addict Biol 2013. [Epub ahead of print]
89. Manvich DF, DePoy LM, Weinshenker D. Dopamine betahydroxylase inhibitors enhance the discriminative stimulus effects of cocaine in rats. J Pharmacol Exp Ther 2013;347: 564-73
90. Gaval-Cruz M, Liles LC, Iuvone PM, Weinshenker D. Chronic inhibition of dopamine beta-hydroxylase facilitates behavioral responses to cocaine in mice. PLoS One 2012;7: E50583
91. Schroeder JP, Epps SA, Grice TW, Weinshenker D. The selective dopamine beta-hydroxylase inhibitor nepicastat attenuates multiple aspects of cocaineseeking behavior. Neuropsychopharmacology 2013;38: 1032-8
92. DeLeon A, Patel NC, Crismon ML. Aripiprazole: A comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 2004;26: 649-66
93. Brown ES, Jeffress J, Liggin JD, et al. Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole. J Clin Psychiatry 2005;66: 756-60
94. Beresford TP, Clapp L, Martin B, et al. Aripiprazole in schizophrenia with cocaine dependence: A pilot study. J Clin Psychopharmacol 2005;25: 363-6
95. Stoops WW, Lile JA, Lofwall MR, Rush CR. The safety, tolerability, and subject-rated effects of acute intranasal cocaine administration during aripiprazole maintenance. Am J Drug Alcohol Abuse 2007;33: 769-76
96. Lile JA, Stoops WW, Hays LR, Rush CR. The safety, tolerability, and subject-rated effects of acute intranasal cocaine administration during aripiprazole maintenance II: Increased aripipirazole dose and maintenance period. Am J Drug Alcohol Abuse 2008;34: 721-9
97. Vorspan F, Bellais L, Keijzer L, Lèpine JP. An open-label study of aripiprazole in nonschizophrenic crackdependent patients. J Clin Psychopharmacol 2008;28: 570-2
98. Haney M, Rubin E, Foltin RW. Aripiprazole maintenance increases smoked cocaine self-Administration in humans. Psychopharmacology (Berl) 2011;216: 379-87
99. Lofwall MR, Nuzzo PA, Campbell C, Walsh SL. Aripiprazole effects on selfadministration and pharmacodynamics of intravenous cocaine and cigarette smoking in humans. Exp Clin Psychopharmacol 2014. [Epub ahead of print]
100. Lile JA, Stoops WW, Glaser PE, et al. Discriminative stimulus, subject-rated and cardiovascular effects of cocaine alone and in combination with aripiprazole in humans. J Psychopharmacol 2011;25: 1469-79
101. Blier P, Bergeron R, de Montigny C. Selective activation of postsynaptic 5-HT 1A receptors induces rapid antidepressant response. Neuropsychopharmacology 1997;16: 333-8
102. Jadhav SA, Gaikwad RV, Gaonkar RK, et al. Dose-dependent response of central dopaminergic systems to buspirone in mice. Indian J Exp Biol 2008;46: 704
103. Bergman J, Roof RA, Furman CA, et al. Modification of cocaine selfadministration by buspirone (buspar-): Potential involvement of D3 and D4 dopamine receptors. Int J Neuropsychopharmacol 2013;16: 445-58
104. Shelton KL, Hendrick ES, Beardsley PM. Efficacy of buspirone for attenuating cocaine and methamphetamine reinstatement in rats. Drug Alcohol Depend 2013;129: 210-16
105. Giannini AJ, Loiselle RH, Graham BH, Folts DJ. Behavioral response to buspirone in cocaine and phencyclidine withdrawal. J Subst Abuse Treat 1993;10: 523-7
106. Moeller FG, Dougherty DM, Barratt ES, et al. The impact of impulsivity on cocaine use and retention in treatment. J Subst Abuse Treat 2001;21: 193-8
107. Adinoff B. Neurobiologic processes in drug reward and addiction. Harv Rev Psychiatry 2004;12: 305-20
108. Johnson BA, Roache JD, Ait-Daoud N, et al. A preliminary randomized, doubleblind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of cocaine dependence. Drug Alcohol Depend 2006;84: 256-63
109. Passie T, Seifert J, Schneider U, Emrich HM. The pharmacology of psilocybin. Addict Biol 2002;7: 357-64
110. Vollenweider FX, Vontobel P, Hell D, Leenders KL. 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man-A PET study with [11C] raclopride. Neuropsychopharmacology 1999;20: 424-33
111. Latini G, Verrotti A, Manco R, et al. Topiramate: Its pharmacological properties and therapeutic efficacy in epilepsy. Mini Rev Med Chem 2008;8: 10-23
112. Johnson BA, Roache JD, Ait-Daoud N, et al. Topiramate's effects on cocaineinduced subjective mood, craving and preference for money over drug taking. Addict Biol 2012;18: 405-16
113. Kampman KM, Pettinati H, Lynch KG, et al. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend 2004;75: 233-40
114. Kadden R, Carroll K, DonoVan D, et al. Cognitive-behavioral coping skills therapy manual: A clinical research guide for treating individuals with alcohol abuse and dependence. National Institute on Alcohol Abuse and Alcoholism, Rockville, MD; 1994
115. Johnson BA, Ait-Daoud N, Wang X-Q, et al. Topiramate for the treatment of cocaine addiction. JAMA Psychiatry 2013;70: 1338
116. Reis AD, Castro LA, Faria R, Laranjeira R. Craving decrease with topiramate in outpatient treatment for cocaine dependence: An open label trial. Rev Bras Psiquiatr 2008;30: 132-5
117. Harris JA, Westbrook RF. Evidence that GABA transmission mediates contextspecific extinction of learned fear. Psychopharmacology 1998;140: 105-15
118. Chhatwal JP, Myers KM, Ressler KJ, Davis M. Regulation of gephyrin and GABAA receptor binding within the amygdala after fear acquisition and extinction. J Neurosci 2005;25: 502-6
119. Mariani JJ, Pavlicova M, Bisaga A, et al. Extended-release mixed amphetamine salts and topiramate for cocaine dependence: A randomized controlled trial. Biol Psychiatry 2012;72: 950-6
120. Lal R, Sukbuntherng J, Tai EH, et al. Arbaclofen placarbil, a novel R-baclofen prodrug: Improved absorption, distribution, metabolism, and elimination properties compared with R-baclofen. J Pharmacol Exp Ther 2009;330: 911-21
121. Ong J, Kerr DI. Clinical potential of GABAB receptor modulators. CNS Drug Rev 2005;11: 317-34
122. Franchitto N, Pelissier F, Lauque D, et al. Self-intoxication with Baclofen in alcohol-dependent patients with coexisting psychiatric illness: An emergency department case series. Alcohol Alcohol 2014;49: 79-83
123. Lile JA, Stoops WW, Allen TS, et al. Baclofen does not alter the reinforcing, subject-rated or cardiovascular effects of intranasal cocaine in humans. Psychopharmacology (Berl) 2004;171: 441-9
124. Haney M, Hart CL, Foltin RW. Effects of baclofen on cocaine selfadministration: Opioid-And nonopioiddependent volunteers. Neuropsychopharmacology 2006;31: 1814-21
125. Rotheram-Fuller E, La Garza De R II, Mahoney JJ III, et al. Subjective and cardiovascular effects of cocaine during treatment with amantadine and baclofen in combination. Psychiatry Res 2007;152: 205-10
126. Shoptaw S, Yang X, Rotheram-Fuller EJ, et al. Randomized placebo-controlled trial of baclofen for cocaine dependence: Preliminary effects for individuals with chronic patterns of cocaine use. J Clin Psychiatry 2003;64: 1440-8
127. Kahn R, Biswas K, Childress A-R, et al. Multi-center trial of baclofen for abstinence initiation in severe cocainedependent individuals. Drug Alcohol Depend 2009;103: 59-64
128. Clements JA, Nimmo WS, Grant IS. Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans. J Pharm Sci 1982;71: 539-42
129. Jansen KL, Darracot-Cankovic R. The nonmedical use of ketamlne, part two: A review of problem use and dependence. J Psychoactive Drugs 2001;33: 151-8
130. Lankenau SE, Bloom JJ, Shin C. Longitudinal trajectories of ketamine use among young injection drug users. Int J Drug Policy 2010;21: 306-14
131. Olthuis JV, Darredeau C, Barrett SP. Substance use initiation: The role of simultaneous polysubstance use. Drug Alcohol Rev 2013;32: 67-71
132. Abdel Rahman MS, Ismail EE. Teratogenic effect of ketamine and cocaine in CF-1 mice. Teratology 2000;61: 291-6
133. Murphy JL. Hypertension and pulmonary oedema associated with ketamine administration in a patient with a history of substance abuse. Can J Anaesth 1993;40: 160-4
134. Browne CA, Lucki I. Antidepressant effects of ketamine: Mechanisms underlying fast-Acting novel antidepressants. Front Pharmacol 2013;4: 161
135. Pandit SK, Dundee JW, Bovill JG. Clinical studies of induction agents XXXVII: Amnesic action of ketamine. Br J Anaesth 1971;43: 362-4
136. Morgan CJA, Perry EB, Cho H-S, et al. Greater vulnerability to the amnestic effects of ketamine in males. Psychopharmacology (Berl) 2006;187: 405-14
137. Albright JA, Stevens SA, Beussman DJ. Detecting ketamine in beverage residues: Application in date rape detection. Drug Test Anal 2011;4: 337-41
138. Miserendino MJ, Sananes CB, Melia KR, Davis M. Blocking of acquisition but not expression of conditioned fearpotentiated startle by NMDA antagonists in the amygdala. Nature 1990;345: 716-18
139. Amara SG, Kuhar MJ. Neurotransmitter transporters: Recent progress. Annu Rev Neurosci 1993;16: 73-93
140. Horne MK, Lee J, Chen F, et al. Long term administration of cocaine or serotonin reuptake inhibitors results in anatomical and neurochemical changes in noradrenergic, dopaminergic and serotonin pathways. J Neurochem 2008;106: 1731-44
141. Holman BL, Carvalho PA, Mendelson J, et al. Brain perfusion is abnormal in cocaine-dependent polydrug users: A study using technetium-99m-HMPAO and ASPECT. J Nucl Med 1991;32: 1206-10
142. Elliott HL, Meredith PA, Sumner DJ, et al. A pharmacodynamic and pharmacokinetic assessment of a new alpha-Adrenoceptor antagonist, doxazosin (UK33274) in normotensive subjects. Br J Clin Pharmacol 1982;13: 699-703
143. Newton TF, La Garza De R II, Brown G, et al. Noradrenergic a1 receptor antagonist treatment attenuates positive subjective effects of cocaine in humans: A randomized trial. PLoS One 2012;7: E30854
144. Shorter D, Lindsay JA, Kosten TR. The alpha-1 adrenergic antagonist doxazosin for treatment of cocaine dependence: A pilot study. Drug Alcohol Depend 2013;131: 66-70
145. Sofuoglu M, Brown S, Babb DA, et al. Carvedilol affects the physiological and behavioral response to smoked cocaine in humans. Drug Alcohol Depend 2000;60: 69-76
146. Self T, Rogers ML, Mancell J, Soberman JE. Carvedilol therapy after cocaine-induced myocardial infarction in patients with asthma. Am J Med Sci 2011;342: 56-61
147. Kampman KM, Volpicelli JR, Mulvaney F, et al. Effectiveness of propranolol for cocaine dependence treatment may depend on cocaine withdrawal symptom severity. Drug Alcohol Depend 2001;63: 69-78
148. Kampman KM, Dackis C, Lynch KG, et al. A double-blind, placebo-controlled trial of amantadine, propranolol, and their combination for the treatment of cocaine dependence in patients with severe cocaine withdrawal symptoms. Drug Alcohol Depend 2006;85: 129-37
149. Ahmadi J, Kampman K, Dackis C. Outcome predictors in cocaine dependence treatment trials. Am J Addict 2006;15: 434-9
150. Misanin JR, Miller RR, Lewis DJ. Retrograde amnesia produced by electroconvulsive shock after reactivation of a consolidated memory trace. Science 1968;160: 554-5
151. Milton AL, Lee JLC, Everitt BJ. Reconsolidation of appetitive memories for both natural and drug reinforcement is dependent on-Adrenergic receptors. Learn Mem 2008;15: 88-92
152. Przybyslawski J, Roullet P, Sara SJ. Attenuation of emotional and nonemotional memories after their reactivation: Role of beta adrenergic receptors. J Neurosci 1999;19: 6623-8
153. Diergaarde L, Schoffelmeer ANM, De Vries TJ. Beta-Adrenoceptor mediated inhibition of long-Term reward-related memory reconsolidation. Behav Brain Res 2006;170: 333-6
154. Dudai Y. Reconsolidation: The advantage of being refocused. Curr Opin Neurobiol 2006;16: 174-8
155. Brunet A, Poundja J, Tremblay J, et al. Trauma reactivation under the influence of propranolol decreases posttraumatic stress symptoms and disorder: 3 openlabel trials. J Clin Psychopharmacol 2011;31: 547-50
156. Saladin ME, Gray KM, McRae-Clark AL, et al. A double blind, placebo-controlled study of the effects of post-retrieval propranolol on reconsolidation of memory for craving and cue reactivity in cocaine dependent humans. Psychopharmacology (Berl) 2013;226: 721-37
157. Evrard I, Legleye S, Cadet-Taïrou A. Composition, purity and perceived quality of street cocaine in France. Int J Drug Policy 2010;21: 399-406
158. Tzeng W-Y, Chang W-T, Chuang J-Y, et al. Disruption of memory reconsolidation impairs storage of other, non-reactivated memory. Neurobiol Learn Mem 2012;97: 241-9
159. Chang S-D, Chen D-Y, Liang KC. Infusion of lidocaine into the dorsal hippocampus before or after the shock training phase impaired conditioned freezing in a two-phase training task of contextual fear conditioning. Neurobiol Learn Mem 2008;89: 95-105
160. Howland RH. Mifepristone as a therapeutic agent in psychiatry. J Psychosoc Nurs Ment Health Serv 2013;51: 11-14
161. Fagen ZM, Mitchum R, Vezina P, McGehee DS. Enhanced nicotinic receptor function and drug abuse vulnerability. J Neurosci 2007;27: 8771-8
162. Saal D, Dong Y, Bonci A, Malenka RC. Drugs of abuse and stress trigger a common synaptic adaptation in dopamine neurons. Neuron 2003;37: 577-82
163. Graf EN, Wheeler RA, Baker DA, et al. Corticosterone acts in the nucleus accumbens to enhance dopamine signaling and potentiate reinstatement of cocaine seeking. J Neurosci 2013;33: 11800-10
164. Patkar AA, Mannelli P, Hill KP, et al. Relationship of prolactin response to meta-chlorophenylpiperazine with severity of drug use in cocaine dependence. Hum Psychopharmacol Clin Exp 2006;21: 367-75
165. Gorelick DA, Simmons MS, Carriero N, Tashkin DP. Characteristics of smoked drug use among cocaine smokers. Am J Addict 1997;6: 237-45
166. Crunelle CL, Miller ML, Booij J, Van Den Brink W. The nicotinic acetylcholine receptor partial agonist varenicline and the treatment of drug dependence: A review. Eur Neuropsychopharmacol 2010;20: 69-79
167. Poling J, Rounsaville B, Gonsai K, et al. The safety and efficacy of varenicline in cocaine using smokers maintained on methadone: A pilot study. Am J Addict 2010;19: 401-8
168. Plebani JG, Lynch KG, Yu Q, et al. Results of an initial clinical trial of varenicline for the treatment of cocaine dependence. Drug Alcohol Depend 2012;121: 163-6
169. Singh S, Loke YK, Spangler JG, Furberg CD. Risk of serious adverse cardiovascular events associated with varenicline: A systematic review and meta-Analysis. CMAJ 2011;183: 1359-66
170. Jenkins TA, Allen AM, Chai SY, et al. Interactions of angiotensin II with central dopamine. Adv Exp Med Biol 1996;396: 93-103
171. Kosten TR, Rosen M, Bond J, et al. Human therapeutic cocaine vaccine: Safety and immunogenicity. Vaccine 2002;20: 1196-204
172. Martell BA, Mitchell E, Poling J, et al. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol Psychiatry 2005;58: 158-64
173. Haney M, Gunderson EW, Jiang H, et al. Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans. Biol Psychiatry 2010;67: 59-65
174. Orson FM, Rossen RD, Shen X, et al. Spontaneous development of IgM anticocaine antibodies in habitual cocaine users: Effect on IgG antibody responses to a cocaine cholera toxin B conjugate vaccine. Am J Addict 2013;22: 169-74
175. Stoops WW, Blackburn JW, Hudson DA, et al. Safety, tolerability and subject-rated effects of acute intranasal cocaine administration during atomoxetine maintenance. Drug Alcohol Depend 2008;92: 282-5
176. Nestler EJ. Is there a common molecular pathway for addictioñ Nat Neurosci 2005;8: 1445-9
177. Bergman J. Medications for stimulant abuse: Agonist-based strategies and preclinical evaluation of the mixed-Action D2 partial agonist aripiprazole (Abilify-). Exp Clin Psychopharmacol 2008;16: 475-83
178. Gorelick DA, Kim YK, Bencherif B, et al. Brain mu-opioid receptor binding: Relationship to relapse to cocaine use after monitored abstinence. Psychopharmacology (Berl) 2008;200: 475-86
179. McClure EA, Gipson CD, Malcolm RJ, et al. Potential role of N-Acetylcysteine in the management of substance use disorders. CNS Drugs 2014;28: 95-106.